Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy

@article{Morgenstern2013CurrentAF,
  title={Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy},
  author={D. Morgenstern and S. Baruchel and M. Irwin},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2013},
  volume={35},
  pages={337–347}
}
  • D. Morgenstern, S. Baruchel, M. Irwin
  • Published 2013
  • Medicine
  • Journal of Pediatric Hematology/Oncology
  • More than half of the patients with high-risk neuroblastoma (NB) will relapse despite intensive multimodal therapy, with an additional 10% to 20% refractory to induction chemotherapy. Management of these patients is challenging, given disease heterogeneity, resistance, and organ toxicity including poor hematological reserve. This review will discuss the current treatment options and consider novel therapies on the horizon. Cytotoxic chemotherapy regimens for relapse and refractory NB typically… CONTINUE READING
    Neuroblastoma: paradigm for precision medicine.
    • 147
    • PDF
    Cancer stem cells in neuroblastoma therapy resistance
    • 6
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 147 REFERENCES